Cost-of-illness of epilepsy in Italy: Data from a multicentre observational study (Episcreen)

Patrizia Berto, P. Tinuper, S. Viaggi, G. Buzzi, A. Bianchi, P. Zolo, P. Riguzzi, L. Volpi, R. Michelucci, C. A. Tassinari, A. Cerullo, E. Lugaresi, R. Di Perri, A. Magaudda, G. Gallitto, C. Gattuso, R. Musolino, M. Tripodi, A. Saltarelli, A. VignoliR. Canger, M. Viri, A. Romeo, E. Cusani Visconti, S. Franceschetti, G. Avanzini, L. Tassi, F. Cardinale, C. Munari, R. Meo, S. Striano, G. Caravaglios, O. Daniele, F. Piccoli, S. Sartori, A. Tartara, R. Cilio, L. Fusco, F. Vigevano, C. Di Bonaventura, F. Fittipaldi, A. T. Giallonardo, M. Manfredi, F. Muzzi, D. Del Priore, M. R. De Feo, O. Mecarelli, A. Montagnini, E. Fontana, B. Dalla Bernardina

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: To investigate the impact of epilepsy in Italy on healthcare resources, producing an average cost per patient per year of follow-up. Design and setting: The Episcreen Project is a multicentre longitudinal Italian observational study; its methodology, organisational network and case report form have been reported in detail elsewhere. Using a subset of patients with epilepsy from this project, we conducted a retrospective cost- of-illness analysis based on clinical records. The analysis was performed from the societal (community) perspective, including both direct and indirect costs. Hospital admissions, day-hospital visits, specialist visits, instrumental examinations, drugs and productivity losses because of visits and hospitalisation were analysed. Each cost variable was valued in 1996 Italian liras (L) using published national tariffs (except for drugs for which published prices were used). A sensitivity analysis was conducted on indirect costs to test the robustness of the assumption that 1 working day lost for each day hospital visit would produce a change of 0.3% in the weight of indirect costs. Patients and participants: Patients analysed in this study were registered in the Episcreen database as at 21 November 1996. They were diagnosed with epilepsy at the last visit, had at least 1 follow-up visit (i.e. at least 1 visit after the enrolment visit), and had at least 12 months of follow-up. Results: The average cost per patient per year was L2 726 116 ($US1767). The average cost per patient was higher for children than for adults [L3 629 997 ($US2353) and L2 362 134 ($US1531), respectively), and for newly diagnosed patients for whom the first diagnosis of epilepsy was addressed at the first Episcreen visit [adults: old referrals L1 304 353 ($US845), new referrals L6 901 374 ($US4473); children: old referrals L2 810 504 ($US1822), new referrals L7 814 400 ($US5065)]. Direct costs represented 87.6% of total costs. The major cost driver was hospitalisation (63.7%), followed by drugs (10.5%), day-hospital visits (4.1%), outpatient visits (3.85%), other tests (3.1%) and electroencephalographs (2.3%). Indirect costs (lost productivity) represented 12.4% of total costs. Sensitivity analysis showed that the results are sensitive to the value attributed to lost productivity. Conclusions: The cost of managing a patient with epilepsy in Italy is influenced by age, syndrome and modality of referral to the centre for epilepsy.

Original languageEnglish
Pages (from-to)197-208
Number of pages12
JournalPharmacoEconomics
Volume17
Issue number2
Publication statusPublished - 2000

Fingerprint

Cost of Illness
Italy
Multicenter Studies
Observational Studies
Epilepsy
Costs and Cost Analysis
Referral and Consultation
Hospitalization
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Berto, P., Tinuper, P., Viaggi, S., Buzzi, G., Bianchi, A., Zolo, P., ... Dalla Bernardina, B. (2000). Cost-of-illness of epilepsy in Italy: Data from a multicentre observational study (Episcreen). PharmacoEconomics, 17(2), 197-208.

Cost-of-illness of epilepsy in Italy : Data from a multicentre observational study (Episcreen). / Berto, Patrizia; Tinuper, P.; Viaggi, S.; Buzzi, G.; Bianchi, A.; Zolo, P.; Riguzzi, P.; Volpi, L.; Michelucci, R.; Tassinari, C. A.; Cerullo, A.; Lugaresi, E.; Di Perri, R.; Magaudda, A.; Gallitto, G.; Gattuso, C.; Musolino, R.; Tripodi, M.; Saltarelli, A.; Vignoli, A.; Canger, R.; Viri, M.; Romeo, A.; Cusani Visconti, E.; Franceschetti, S.; Avanzini, G.; Tassi, L.; Cardinale, F.; Munari, C.; Meo, R.; Striano, S.; Caravaglios, G.; Daniele, O.; Piccoli, F.; Sartori, S.; Tartara, A.; Cilio, R.; Fusco, L.; Vigevano, F.; Di Bonaventura, C.; Fittipaldi, F.; Giallonardo, A. T.; Manfredi, M.; Muzzi, F.; Del Priore, D.; De Feo, M. R.; Mecarelli, O.; Montagnini, A.; Fontana, E.; Dalla Bernardina, B.

In: PharmacoEconomics, Vol. 17, No. 2, 2000, p. 197-208.

Research output: Contribution to journalArticle

Berto, P, Tinuper, P, Viaggi, S, Buzzi, G, Bianchi, A, Zolo, P, Riguzzi, P, Volpi, L, Michelucci, R, Tassinari, CA, Cerullo, A, Lugaresi, E, Di Perri, R, Magaudda, A, Gallitto, G, Gattuso, C, Musolino, R, Tripodi, M, Saltarelli, A, Vignoli, A, Canger, R, Viri, M, Romeo, A, Cusani Visconti, E, Franceschetti, S, Avanzini, G, Tassi, L, Cardinale, F, Munari, C, Meo, R, Striano, S, Caravaglios, G, Daniele, O, Piccoli, F, Sartori, S, Tartara, A, Cilio, R, Fusco, L, Vigevano, F, Di Bonaventura, C, Fittipaldi, F, Giallonardo, AT, Manfredi, M, Muzzi, F, Del Priore, D, De Feo, MR, Mecarelli, O, Montagnini, A, Fontana, E & Dalla Bernardina, B 2000, 'Cost-of-illness of epilepsy in Italy: Data from a multicentre observational study (Episcreen)', PharmacoEconomics, vol. 17, no. 2, pp. 197-208.
Berto, Patrizia ; Tinuper, P. ; Viaggi, S. ; Buzzi, G. ; Bianchi, A. ; Zolo, P. ; Riguzzi, P. ; Volpi, L. ; Michelucci, R. ; Tassinari, C. A. ; Cerullo, A. ; Lugaresi, E. ; Di Perri, R. ; Magaudda, A. ; Gallitto, G. ; Gattuso, C. ; Musolino, R. ; Tripodi, M. ; Saltarelli, A. ; Vignoli, A. ; Canger, R. ; Viri, M. ; Romeo, A. ; Cusani Visconti, E. ; Franceschetti, S. ; Avanzini, G. ; Tassi, L. ; Cardinale, F. ; Munari, C. ; Meo, R. ; Striano, S. ; Caravaglios, G. ; Daniele, O. ; Piccoli, F. ; Sartori, S. ; Tartara, A. ; Cilio, R. ; Fusco, L. ; Vigevano, F. ; Di Bonaventura, C. ; Fittipaldi, F. ; Giallonardo, A. T. ; Manfredi, M. ; Muzzi, F. ; Del Priore, D. ; De Feo, M. R. ; Mecarelli, O. ; Montagnini, A. ; Fontana, E. ; Dalla Bernardina, B. / Cost-of-illness of epilepsy in Italy : Data from a multicentre observational study (Episcreen). In: PharmacoEconomics. 2000 ; Vol. 17, No. 2. pp. 197-208.
@article{7b443bbb6330459e8b4ce7c6bde70ad0,
title = "Cost-of-illness of epilepsy in Italy: Data from a multicentre observational study (Episcreen)",
abstract = "Objective: To investigate the impact of epilepsy in Italy on healthcare resources, producing an average cost per patient per year of follow-up. Design and setting: The Episcreen Project is a multicentre longitudinal Italian observational study; its methodology, organisational network and case report form have been reported in detail elsewhere. Using a subset of patients with epilepsy from this project, we conducted a retrospective cost- of-illness analysis based on clinical records. The analysis was performed from the societal (community) perspective, including both direct and indirect costs. Hospital admissions, day-hospital visits, specialist visits, instrumental examinations, drugs and productivity losses because of visits and hospitalisation were analysed. Each cost variable was valued in 1996 Italian liras (L) using published national tariffs (except for drugs for which published prices were used). A sensitivity analysis was conducted on indirect costs to test the robustness of the assumption that 1 working day lost for each day hospital visit would produce a change of 0.3{\%} in the weight of indirect costs. Patients and participants: Patients analysed in this study were registered in the Episcreen database as at 21 November 1996. They were diagnosed with epilepsy at the last visit, had at least 1 follow-up visit (i.e. at least 1 visit after the enrolment visit), and had at least 12 months of follow-up. Results: The average cost per patient per year was L2 726 116 ($US1767). The average cost per patient was higher for children than for adults [L3 629 997 ($US2353) and L2 362 134 ($US1531), respectively), and for newly diagnosed patients for whom the first diagnosis of epilepsy was addressed at the first Episcreen visit [adults: old referrals L1 304 353 ($US845), new referrals L6 901 374 ($US4473); children: old referrals L2 810 504 ($US1822), new referrals L7 814 400 ($US5065)]. Direct costs represented 87.6{\%} of total costs. The major cost driver was hospitalisation (63.7{\%}), followed by drugs (10.5{\%}), day-hospital visits (4.1{\%}), outpatient visits (3.85{\%}), other tests (3.1{\%}) and electroencephalographs (2.3{\%}). Indirect costs (lost productivity) represented 12.4{\%} of total costs. Sensitivity analysis showed that the results are sensitive to the value attributed to lost productivity. Conclusions: The cost of managing a patient with epilepsy in Italy is influenced by age, syndrome and modality of referral to the centre for epilepsy.",
author = "Patrizia Berto and P. Tinuper and S. Viaggi and G. Buzzi and A. Bianchi and P. Zolo and P. Riguzzi and L. Volpi and R. Michelucci and Tassinari, {C. A.} and A. Cerullo and E. Lugaresi and {Di Perri}, R. and A. Magaudda and G. Gallitto and C. Gattuso and R. Musolino and M. Tripodi and A. Saltarelli and A. Vignoli and R. Canger and M. Viri and A. Romeo and {Cusani Visconti}, E. and S. Franceschetti and G. Avanzini and L. Tassi and F. Cardinale and C. Munari and R. Meo and S. Striano and G. Caravaglios and O. Daniele and F. Piccoli and S. Sartori and A. Tartara and R. Cilio and L. Fusco and F. Vigevano and {Di Bonaventura}, C. and F. Fittipaldi and Giallonardo, {A. T.} and M. Manfredi and F. Muzzi and {Del Priore}, D. and {De Feo}, {M. R.} and O. Mecarelli and A. Montagnini and E. Fontana and {Dalla Bernardina}, B.",
year = "2000",
language = "English",
volume = "17",
pages = "197--208",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Cost-of-illness of epilepsy in Italy

T2 - Data from a multicentre observational study (Episcreen)

AU - Berto, Patrizia

AU - Tinuper, P.

AU - Viaggi, S.

AU - Buzzi, G.

AU - Bianchi, A.

AU - Zolo, P.

AU - Riguzzi, P.

AU - Volpi, L.

AU - Michelucci, R.

AU - Tassinari, C. A.

AU - Cerullo, A.

AU - Lugaresi, E.

AU - Di Perri, R.

AU - Magaudda, A.

AU - Gallitto, G.

AU - Gattuso, C.

AU - Musolino, R.

AU - Tripodi, M.

AU - Saltarelli, A.

AU - Vignoli, A.

AU - Canger, R.

AU - Viri, M.

AU - Romeo, A.

AU - Cusani Visconti, E.

AU - Franceschetti, S.

AU - Avanzini, G.

AU - Tassi, L.

AU - Cardinale, F.

AU - Munari, C.

AU - Meo, R.

AU - Striano, S.

AU - Caravaglios, G.

AU - Daniele, O.

AU - Piccoli, F.

AU - Sartori, S.

AU - Tartara, A.

AU - Cilio, R.

AU - Fusco, L.

AU - Vigevano, F.

AU - Di Bonaventura, C.

AU - Fittipaldi, F.

AU - Giallonardo, A. T.

AU - Manfredi, M.

AU - Muzzi, F.

AU - Del Priore, D.

AU - De Feo, M. R.

AU - Mecarelli, O.

AU - Montagnini, A.

AU - Fontana, E.

AU - Dalla Bernardina, B.

PY - 2000

Y1 - 2000

N2 - Objective: To investigate the impact of epilepsy in Italy on healthcare resources, producing an average cost per patient per year of follow-up. Design and setting: The Episcreen Project is a multicentre longitudinal Italian observational study; its methodology, organisational network and case report form have been reported in detail elsewhere. Using a subset of patients with epilepsy from this project, we conducted a retrospective cost- of-illness analysis based on clinical records. The analysis was performed from the societal (community) perspective, including both direct and indirect costs. Hospital admissions, day-hospital visits, specialist visits, instrumental examinations, drugs and productivity losses because of visits and hospitalisation were analysed. Each cost variable was valued in 1996 Italian liras (L) using published national tariffs (except for drugs for which published prices were used). A sensitivity analysis was conducted on indirect costs to test the robustness of the assumption that 1 working day lost for each day hospital visit would produce a change of 0.3% in the weight of indirect costs. Patients and participants: Patients analysed in this study were registered in the Episcreen database as at 21 November 1996. They were diagnosed with epilepsy at the last visit, had at least 1 follow-up visit (i.e. at least 1 visit after the enrolment visit), and had at least 12 months of follow-up. Results: The average cost per patient per year was L2 726 116 ($US1767). The average cost per patient was higher for children than for adults [L3 629 997 ($US2353) and L2 362 134 ($US1531), respectively), and for newly diagnosed patients for whom the first diagnosis of epilepsy was addressed at the first Episcreen visit [adults: old referrals L1 304 353 ($US845), new referrals L6 901 374 ($US4473); children: old referrals L2 810 504 ($US1822), new referrals L7 814 400 ($US5065)]. Direct costs represented 87.6% of total costs. The major cost driver was hospitalisation (63.7%), followed by drugs (10.5%), day-hospital visits (4.1%), outpatient visits (3.85%), other tests (3.1%) and electroencephalographs (2.3%). Indirect costs (lost productivity) represented 12.4% of total costs. Sensitivity analysis showed that the results are sensitive to the value attributed to lost productivity. Conclusions: The cost of managing a patient with epilepsy in Italy is influenced by age, syndrome and modality of referral to the centre for epilepsy.

AB - Objective: To investigate the impact of epilepsy in Italy on healthcare resources, producing an average cost per patient per year of follow-up. Design and setting: The Episcreen Project is a multicentre longitudinal Italian observational study; its methodology, organisational network and case report form have been reported in detail elsewhere. Using a subset of patients with epilepsy from this project, we conducted a retrospective cost- of-illness analysis based on clinical records. The analysis was performed from the societal (community) perspective, including both direct and indirect costs. Hospital admissions, day-hospital visits, specialist visits, instrumental examinations, drugs and productivity losses because of visits and hospitalisation were analysed. Each cost variable was valued in 1996 Italian liras (L) using published national tariffs (except for drugs for which published prices were used). A sensitivity analysis was conducted on indirect costs to test the robustness of the assumption that 1 working day lost for each day hospital visit would produce a change of 0.3% in the weight of indirect costs. Patients and participants: Patients analysed in this study were registered in the Episcreen database as at 21 November 1996. They were diagnosed with epilepsy at the last visit, had at least 1 follow-up visit (i.e. at least 1 visit after the enrolment visit), and had at least 12 months of follow-up. Results: The average cost per patient per year was L2 726 116 ($US1767). The average cost per patient was higher for children than for adults [L3 629 997 ($US2353) and L2 362 134 ($US1531), respectively), and for newly diagnosed patients for whom the first diagnosis of epilepsy was addressed at the first Episcreen visit [adults: old referrals L1 304 353 ($US845), new referrals L6 901 374 ($US4473); children: old referrals L2 810 504 ($US1822), new referrals L7 814 400 ($US5065)]. Direct costs represented 87.6% of total costs. The major cost driver was hospitalisation (63.7%), followed by drugs (10.5%), day-hospital visits (4.1%), outpatient visits (3.85%), other tests (3.1%) and electroencephalographs (2.3%). Indirect costs (lost productivity) represented 12.4% of total costs. Sensitivity analysis showed that the results are sensitive to the value attributed to lost productivity. Conclusions: The cost of managing a patient with epilepsy in Italy is influenced by age, syndrome and modality of referral to the centre for epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0034110267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034110267&partnerID=8YFLogxK

M3 - Article

C2 - 10947342

AN - SCOPUS:0034110267

VL - 17

SP - 197

EP - 208

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 2

ER -